To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Gynae-Oncology cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
PROMPTPhase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer | |
---|---|
Local Project Reference: | 17/0629 |
Principal Investigator: | Prof. Jonathan Ledermann |
Drug Class/ Treatment: | Pembrolizumab (PD-1 Inhibitor) + Paclitaxel (Chemotherapy) |
Patient Population: |
|
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
BOUQUET (WO42178)A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors | |
---|---|
Local Project Reference: | 139231 |
Principal Investigator: | Dr. Rowan Miller |
Drug Class/ Treatment: | Platform trial of various Immunotherapy and Targeted Therapy Agents. |
Patient Population: | Persistent Or Recurrent Rare Epithelial Ovarian Tumors |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
EP0057-201 (Ellipses)A Phase 2 study of EP0057 and Olaparib in ovarian cancer patients: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease; Cohort 2 – had at least 1 prior line of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance. | |
---|---|
Local Project Reference: | 135878 |
Principal Investigator: | Dr. Rowan Miller |
Drug Class/ Treatment: | EP0057 (Nanoparticle-Drug Conjugate Topoisomerase 1 Inhibitor) + Olaparib (PARP Inhibitor) |
Patient Population: | Ovarian Cancer |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |